Navigation Links
deCODE genetics Announces Webcast of Conference Call to Discuss First Quarter 2009 Financial Results
Date:5/7/2009

REYKJAVIK, Iceland, May 7 /PRNewswire-FirstCall/ -- deCODE genetics, Inc. (Nasdaq: DCGN) today announced that it will report its first quarter 2009 financial results in a press release to be issued on Monday, May 11, after the close of the market in New York. The company will host a live webcast of its conference call to discuss these results and recent operating highlights on Tuesday, May 12, at 8am Eastern Daylight Time/ 12pm GMT/1pm British Summer Time.

The webcast can be accessed through the Investors page of deCODE's website, http://www.decode.com, or through http://www.earnings.com. Please log in to the webcast 15 minutes prior to the scheduled start of the call. The call will be archived for at least a week on each site. For those unable to listen to the webcast because of company firewall or other issues, a digitized audio replay will also be available by telephone from approximately 10am EDT on Tuesday, May 12 and for one week thereafter. The dial-in replay numbers are: 1-(800)-475-6701 in the U.S., and +1-(320)-365-3844 for those calling from outside the U.S. The access code is 100482.

Any statements contained in this presentation that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results, and the timing of events, to differ materially from those described in the forward-looking statements. These risks and uncertainties include, among others, those relating to our ability to obtain sufficient financing to continue as a going concern, the outcome of the review of the continued listing of our common stock on The Nasdaq Stock Market, our ability to develop and market diagnostic products, the level of third party reimbursement for our products, risks related to preclinical and clinical development of pharmaceutical products, including the identification of compounds and the completion of clinical trials, our ability to form collaborative relationships, the effect of government regulation and the regulatory approval processes, market acceptance, our ability to obtain and protect intellectual property rights for our products, dependence on collaborative relationships, the effect of competitive products, industry trends and other risks identified in deCODE's filings with the Securities and Exchange Commission, including, without limitation, the risk factors identified in our most recent Annual Report on Form 10-K and any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. deCODE undertakes no obligation to update or alter these forward-looking statements as a result of new information, future events or otherwise.

    Contacts:
    deCODE genetics
    Gisli Arnason
    +354-570-1825
    gisli.arnason@decode.is



'/>"/>
SOURCE deCODE genetics Inc
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Nasdaq Stays Suspension of Trading in deCODE Stock
2. deCODE and Celera Partner to Expand use of deCODE Risk Markers for Heart Attack, Stroke and Diabetes
3. deCODE to Utilize Grace Period for Interest Payment on Senior Convertible Notes
4. deCODE genetics Announces Webcast of Conference Call to Discuss Full-year 2008 Financial Results
5. Multinational deCODE Study Identifies New Link Between Inflammation and Heart Attack
6. deCODE Announces Transfer of the Listing of its Common Stock from Nasdaq Global Market to Nasdaq Capital Market
7. deCODE Discovers First Genetic Variant Conferring Increased Risk of Essential Tremor
8. deCODE Sells Auction Rate Securities
9. Introducing deCODEme Cardio(TM) and deCODEme Cancer(TM)
10. deCODE Discovers Common Genetic Variations Contributing to Low Bone Mineral Density and Risk of Osteoporosis
11. deCODE to Integrate New Genetic Risk Factor for Type 2 Diabetes Into Its deCODEme(TM) Personal Genome Scan Service
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... , ... October 11, 2017 , ... ComplianceOnline’s Medical Device ... on 7th and 8th June 2018 in San Francisco, CA. The Summit brings together ... as several distinguished CEOs, board directors and government officials from around the world to ...
(Date:10/11/2017)... ... October 11, 2017 , ... Disappearing forests and increased emissions ... over 5.5 million people each year. Especially those living in larger cities are affected ... based in one of the most pollution-affected countries globally - decided to take action. ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... conjugate (ADC) therapeutics, today confirmed licensing rights that give it exclusive global ... technology developed in collaboration with Children’s Hospital Los Angeles (CHLA). Additionally, ...
(Date:10/10/2017)... Oct. 10, 2017 SomaGenics announced the receipt ... to develop RealSeq®-SC (Single Cell), expected to be the ... RNAs (including microRNAs) from single cells using NGS methods. ... need to accelerate development of approaches to analyze the ... "New techniques for measuring levels of mRNAs in ...
Breaking Biology Technology:
(Date:4/13/2017)... April 13, 2017 UBM,s Advanced Design and ... will feature emerging and evolving technology through its 3D ... will run alongside the expo portion of the event ... and demonstrations focused on trending topics within 3D printing ... and manufacturing event will take place June 13-15, 2017 at ...
(Date:4/11/2017)... NXT-ID, Inc. (NASDAQ:   NXTD ) ... appointment of independent Directors Mr. Robin D. Richards ... Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive ... their guidance and benefiting from their considerable expertise as we ...
(Date:4/4/2017)... April 4, 2017   EyeLock LLC , a ... the United States Patent and Trademark Office (USPTO) has ... the linking of an iris image with a face ... represents the company,s 45 th issued patent. ... very timely given the multi-modal biometric capabilities that have ...
Breaking Biology News(10 mins):